Abstract 330P
Background
After radiotherapy (RT) to the left breast, the long-term risk of developing various cardiovascular diseases may increase. In our study, we present how deep inspiration treatment changes the doses of organs at risk (OAR), especially the heart. Furthermore, we examined if there is a relationship between the size of the irradiated target area and the dose on the heart.
Methods
From May 2016 to August 2020, 503 patients with left-sided breast cancer underwent RT at our institute. Since May 2018, we have treated our patients in deep breathing (DIBH) using the “voluntary breath-hold” technique. We compared the Dmean and Dmax values for the most critical OAR (left lung, heart, left ventricle, LAD-left anterior descending artery) based on the two treatment methodologies. Subsequently, both groups were then further subdivided into whether the treatment was given by standard fractionation or hypofractionation and created 3-3 groups based on the size of the target area (PTV).
Results
In patients treated with normal fractionation in DIBH vs. without, the doses of the OARs were the following: lung Dmean: 9.3 Gy vs. 9.96 Gy (p=0.029), left ventricle Dmean: 3.52 Gy vs. 7.56 Gy (p=2.69E-27), heart Dmean: 2.78 vs. 5.31 (p=1.11E-24), LAD Dmean 12.17 vs. 25.91 Gy (p=4.63E-24) respectively. In the hypofractionated group with vs. without DIBH the values were lung Dmean: 7.43 Gy vs. 8.08 Gy (p=0.17), left ventricle Dmean: 3.48 Gy vs 6.4 Gy (p=2.64E-10), heart Dmean: 2.64 vs 4.62 (p=2.96E-08), LAD Dmean 11.46 vs 18.35 Gy (p=3.37E-06) respectively. In the standard fractionated group, the average doses for each structure decreased mostly in women with large breast sizes after DIBH treatment. Generally, as the breast size increases, the values of the left ventricle, heart, and LAD increase, whilst the values of the lungs decrease. Although, a significant difference could only be detected in a few categories.
Conclusions
DIBH RT of the left breast significantly reduces radiation exposure to crucial OAR than free-breathing radiation therapy. At the same time, the coverage of the target area does not change, and our results suggest that this benefit is most pronounced in patients with large breast sizes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
263P - Efficacy and safety of neoadjuvant chemotherapy combination with pembrolizumab in triple-negative breast cancer: Real-world data
Presenter: Layal Rached
Session: Poster session 02
264P - Tumor-infiltrating lymphocytes (TILs) for prediction of response to platinum-based neoadjuvant chemotherapy (NACT) in triple-negative breast cancer (TNBC): Final analysis
Presenter: Sheyda Abdullaeva
Session: Poster session 02
265P - Effect of HER2-low-positive status on neoadjuvant chemotherapy and survival outcome of breast cancer: A 10-year dual-center retrospective study
Presenter: Yijun Li
Session: Poster session 02
266P - Discontinuation rate and serious adverse events of chemoimmunotherapy as neoadjuvant treatment for triple-negative breast cancer: A systematic review and meta-analysis
Presenter: Francesca Schipilliti
Session: Poster session 02
267P - Pathological complete response after neoadjuvant chemotherapy plus pertuzumab and trastuzumab for HER2+ early breast cancer: Real-world data from NeoPowER study
Presenter: Fabio Canino
Session: Poster session 02
268P - Evaluating the efficacy of adjuvant capecitabine in triple-negative breast cancer patients with residual disease: A real-world evidence study
Presenter: Min Jeong Kim
Session: Poster session 02
269P - Achieving treatment goals in elderly breast cancer patients with neoadjuvant chemotherapy: A remarkable insight
Presenter: Eda Caliskan Yildirim
Session: Poster session 02
270P - Influence of neoadjuvant chemotherapy-induced short-term amenorrhea on pathologic response and treatment outcome in ER+HER2- breast cancer
Presenter: Seung Eun Lee
Session: Poster session 02
271P - First clinical demonstration of the predictive value of tissue nanomechanical signature in breast cancer patients in neoadjuvant therapy setting
Presenter: Sara Nizzero
Session: Poster session 02